PSMA Evaluation in HER2-negative Breast Cancer
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Recruiting
Phase 2
Interventional Study
Breast Cancer
HER2-negative Breast Cancer
Metastatic Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 13 (estimated)
- Sponsor
- University of Wisconsin, Madison · Other
Who this trial is looking for
This trial is looking for women with a specific type of metastatic breast cancer. Participants will help researchers understand how a certain protein relates to cancer treatment over a period of about 3 days.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with metastatic HER2-negative breast cancer
- I have androgen receptor expression of 10% or more
You may not be able to join if
- I have another active malignancy
- I am unable to lie flat during scans
- I have a medical condition that affects my safety during the study
- I am pregnant or breastfeeding
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen t…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients diagnosed with metastatic HER2-negative breast cancer AR expression of ≥ 10%
Exclusion Criteria:
* Other (non-breast) known active malignancy. Participants with previously treated cancers which are in remission or have no evidence of disease are eligible.
* Unable t…
Contacts